gp100: 280-288(288V) Peptide Vaccine
DRACPC ID DRACPC0056
Active Ingredients gp100: 280-288(288V) Peptide Vaccine
Description A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. gp100:280-288(288V) peptide has a valine substitution at amino acid position 288 to improve immunogenicity. Vaccination with gp100:280-288(288V) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.
Synonyms Ovemotide; gp100: 280-288(288V) Peptide Vaccine
Type Biotech
Disease Melanoma
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula C46H71N9O14
Molecular Weight 974.1
Active Sequence YLEPGPVTV
Sequence Length 9
Modification None
IUPAC Name (4S)-4-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2S)-2-[[2-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid
InChI InChI=1S/C46H71N9O14/c1-23(2)20-31(50-39(61)29(47)21-27-12-14-28(57)15-13-27)40(62)49-30(16-17-35(59)60)45(67)55-19-9-10-32(55)41(63)48-22-34(58)54-18-8-11-33(54)42(64)51-36(24(3)4)43(65)53-38(26(7)56)44(66)52-37(25(5)6)46(68)69/h12-15,23-26,29-33,36-38,56-57H,8-11,16-22,47H2,1-7H3,(H,48,63)(H,49,62)(H,50,61)(H,51,64)(H,52,66)(H,53,65)(H,59,60)(H,68,69)/t26-,29+,30+,31+,32+,33+,36+,37+,38+/m1/s1
InChI_Key POVNCJSPYFCWJR-USZUGGBUSA-N
SMILES O=C(O)CC[C@H](NC([C@@H](NC([C@@H](N)CC1=CC=C(O)C=C1)=O)CC(C)C)=O)C(N2[C@H](C(NCC(N3[C@H](C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@H](C(O)=O)C(C)C)=O)=O)=O)CCC3)=O)=O)CCC2)=O
External Codes
PubChem CID 9919490
DrugBank Accession Number Not available
NCI Thesaurus Code C49042
UNII Not available
CAS 181477-91-8
Drug approval
Drug indication
Investigated for use/treatment in melanoma.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00357461 | A Randomized Phase II Study of Fixed Dose Ipilimumab (MDX-010) 10 mg/kg Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 VG for Previously Treated HLA-A * 0201 Positive Subjects With Stage IV Melanoma | Melanoma (Skin) | Phase 1 | Treatment |
| NCT01176461 | A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma | Melanoma (Skin) | Phase 1 | Treatment |
| NCT01176474 | A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | Melanoma (Skin) | Phase 1 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
